ARCHIVES

Fidaxomicin for CDI Therapy More Cost-Effective Than Vancomycin, Study Says

This article is from The Cancer Letter archive.

Vol. 37 No. 9 | September 26, 2014

Download PDF Visit The Full Archive

Related Articles

QOL Of Young Survivors Equal To Other Children

February 25, 2005

Melanoma Vaccine Near Phase 3, Other Studies Discussed At ACS Seminar

April 13, 1990

In Brief: Robert Cooper, Regional Cancer Center Director, Dead At 59; NCI Critic Epstein Invited to NCAB

April 3, 1992

Hammer Goes Public With Appeal for Increased Funding

March 14, 1986

Study Finds Short Term Tests Predict Carcinogenicity

April 25, 1980

NCA Urges Switching More Funds To Grants From Contract Programs Over Entire Three Years

July 2, 1976